title: FDG uptake after intraarterial chemotherapy in head and neck cancer.
abstract: OBJECTIVE
  The intraarterial chemotherapy (i.a.CHT) using high dose cisplatin combined with systemic neutralization in patients with head and neck cancer (HNSCC) is used to reduce the tumor volume preoperatively. Aim of the study is the evaluation of the influence of i.a.CHT on the metabolism of fluor-18-deoxyglucose (FDG) in the primary and lymph nodes (LN). The value of FDG positron emission tomography (PET) preoperative and as follow-up method after i.a.CHT is examined.
  
  
  METHODS
  Altogether 16 patients with HNSCC underwent two preoperative FDG PET examinations: the baseline examination one week before and the follow-up three weeks after i.a.CHT. The SUVmax values of the primary and the LN and LN metastases were evaluated and compared with each other and the histopathology.
  
  
  RESULTS
  The SUVmax value of the primary decreased after i.a.CHT significantly from a median (25 (th) percentile/75 (th) percentile) of 6.4 (4.1/7.8) to 3.6 (2.4/6.7) (p = 0.01). In 11 out of 16 patients cervical LN metastases were detected. The cervical LN metastases showed a decrease of the SUVmax value from 3.6 (2.3/4.8) in the pretreatment examination to 2.3 (1.7/3.6) after i.a.CHT (p = 0.008). Only in one patient with LN metastases the SUVmax of the nodes increased. The histopathologically measured size of the LN metastases ranged from 2 to 30 mm. Non malignant LN did not reveal a significant SUVmax decrease after i.a.CHT (p = 0.13).
  
  
  CONCLUSIONS
  As expected, primaries of HNSCC showed a significant reduction of SUV after i.a.CHT. Compared to the primary the SUVmax decrease in LN metastases was less, but also significant. Since cytotoxic levels of cisplatin do not occur systemic, postinflammatory reactions of the LN or a lymphatic drainage of the chemotherapeutic drug into the LN could be an explanation. PET for staging of HNSCC must thus be performed prior to i.a.CHT.
authors.affiliation: Gemeinschaftspraxis Nuklearmedizin, Rheinstr. 7-9, 64283 Darmstadt, Germany. doebert@em.uni-frankfurt.de
authors.forename: N
authors.initials: N
authors.lastname: Döbert
authors.forename: A F
authors.initials: AF
authors.lastname: Kovács
authors.forename: C
authors.initials: C
authors.lastname: Menzel
authors.forename: K
authors.initials: K
authors.lastname: Engels
authors.forename: W T
authors.initials: WT
authors.lastname: Kranert
authors.forename: F
authors.initials: F
authors.lastname: Grünwald
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001692:Biological Transport; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18